Ruvacare? + ACT? + GMB?
https://theralase.com/pressrelease/theralase-discovers-new-anti-cancer-vaccine/
Next steps planned by the Company to commercialize this technology include: optimization of the pre-clinical animal models, followed by a Phase Ib clinical study in a patient population presenting with GBM disease and pre-existing tolerance mechanisms, which are actively retarding the immune recognition and destruction of tumours in these cancer patients.
Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase, stated that, “In order to be effective, an anti-cancer vaccine must have an ample supply of antigens and be able to provide secondary responses required to stimulate the body to elicit an effective immune response. The Theralase anti-cancer vaccine has both, possessing multiple tumour antigens and adjuvants such as: TNFa and IL-1b. This anti-cancer vaccine could be used along with current debulking strategies, to help eliminate any residual disease. It is also able to serve as a protective vaccine to target and eliminate any possible relapses.”
https://theralase.com/pressrelease/theralase-discovers-cannabinoid-increases-efficacy-of-patented-anti-cancer-technology-in-destruction-of-brain-cancer/
The initial results reported are the first of a set of experiments planned by our scientific research team in the field of combining cannabinoids with Theralase’s PDT technology and also our anti-cancer vaccine, RuVaCare, in the destruction of human cancers. We believe this research will provide a strong foundation for a “first-in-man” clinical study, where the Company’s patented anti-cancer technology and / or anti-cancer vaccine will be combined with cannabinoid(s) in the treatment of cancer.Dr. Mandel concluded by saying that, “This latest preclinical research lays the groundwork for the Company to actively seek strategic partnerships in the co-development of this combined technology for the treatment of specific human cancers, such as GBM. The Company plans to explore these avenues in the immediate future, with the hopes of securing a joint venture with a company interested in the development of this combination technology, such as a Canadian cannabis producer.”
======================
https://biotechnologyfocus.ca/theralase-improves-delivery-schedule-of-anti-cancer-vaccine-to-eradicate-brain-cancer/
“Theralase has designed and put into development a specific autologous (prepared from the patient’s own cancer cells) anti-cancer vaccine,” says Arkady Mandel M.D., Ph.D., chief scientific officer, Theralase. “In the latest research, utilizing the RG2 cell line as a model of human GBM, Theralase has demonstrated that its anti-cancer vaccine is effective. The anti-cancer vaccine is personalized and designed to train the patient’s immune system to develop a specific immune response creating anti-cancer immune cells that remember, hunt, recognize and kill a patient’s brain cancer cells regardless of where they may be located in the body.”
This anti-cancer vaccine could be used to target and eliminate any recurrences, post-primary treatment, by delivering vaccinations to the patient from a stored bank of their own patient specific anti-cancer vaccines.”
Theralase is in the process of developing two separate clinical treatment paths for patients who have been diagnosed with GBM to safely and effectively destroy the tumour with minimal side effects.
In the first phase of the GBM clinical study, the participant will receive primary treatment, such as surgical debridement, temozolomide (an oral chemotherapy drug) and/or radiation therapy. They will then receive the vaccine created from the patient’s own tumour cells to stimulate the body’s immune system to destroy residual GBM cancer cells.
During the second phase, the participant will receive an intravenous injection of Rutherrin, a patented PDC (TLD-1433) drug formulation combined with transferrin, to then activate it via laser light somewhere between 8 to 24 hours after injection. This time is necessary to allow the drug to cross the blood-brain barrier and be absorbed into the cancer cells.
Additional PDT and/or radiation treatment would then occur to destroy any residual tumours, as required, followed by the Theralase vaccine.
==================================
https://ca.linkedin.com/in/manjuam
Manjunatha Ankathatti Munegowda, DVM, MS, PhD, mMBA
Research Scientist (Cancer therapy - Immunotherapy)
Theralase Technologies Inc.
April 2016 – Present 3 years 1 month
Toronto, Canada Area
Working on novel cancer therapeutic strategies. Including cancer immunotherapy and photodynamic therapy.
My key achievements include:
• Key person in identifying strategic partners, communicating with them, presenting our data. This is being done to speed up clinical development of our products.
• Understanding the mechanism of tumor specific uptake of one of the lead compound.
• Development and evaluation of novel cancer vaccine.
• Developing in-vivo model systems to evaluate our compounds.
• Identifying translational biomarkers for therapeutic efficacy and patient selection.